304 related articles for article (PubMed ID: 25468897)
41. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
Yokota T; Nakamura A; Nagata T; Saito T; Kobayashi M; Aoki Y; Echigoya Y; Partridge T; Hoffman EP; Takeda S
Nucleic Acid Ther; 2012 Oct; 22(5):306-15. PubMed ID: 22888777
[TBL] [Abstract][Full Text] [Related]
42. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.
Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K
J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic/Pharmacodynamic Modeling of a Cell-Penetrating Peptide Phosphorodiamidate Morpholino Oligomer in mdx Mice.
Mukashyaka MC; Wu CL; Ha K; Zhang J; Wood J; Foley S; Mastis B; Jungels N; Sun H; Shadid M; Harriman S; Hadcock JR
Pharm Res; 2021 Oct; 38(10):1731-1745. PubMed ID: 34671920
[TBL] [Abstract][Full Text] [Related]
44. Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy.
Betts CA; Wood MJ
Curr Pharm Des; 2013; 19(16):2948-62. PubMed ID: 23140454
[TBL] [Abstract][Full Text] [Related]
45. A
Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
[TBL] [Abstract][Full Text] [Related]
46. Systemic Injection of Peptide-PMOs into Humanized DMD Mice and Evaluation by RT-PCR and ELISA.
Melo D; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():263-273. PubMed ID: 30171547
[TBL] [Abstract][Full Text] [Related]
47. Amphiphilic lipopeptide significantly enhances uptake of charge-neutral splice switching morpholino oligonucleotide in spinal muscular atrophy patient-derived fibroblasts.
Tajik-Ahmadabad B; Polyzos A; Separovic F; Shabanpoor F
Int J Pharm; 2017 Oct; 532(1):21-28. PubMed ID: 28864392
[TBL] [Abstract][Full Text] [Related]
48. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.
Lehto T; Castillo Alvarez A; Gauck S; Gait MJ; Coursindel T; Wood MJ; Lebleu B; Boisguerin P
Nucleic Acids Res; 2014 Mar; 42(5):3207-17. PubMed ID: 24366877
[TBL] [Abstract][Full Text] [Related]
49. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
Hiller M; Spitali P; Datson N; Aartsma-Rus A
Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
[TBL] [Abstract][Full Text] [Related]
50. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
51. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
52. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.
Popplewell LJ; Adkin C; Arechavala-Gomeza V; Aartsma-Rus A; de Winter CL; Wilton SD; Morgan JE; Muntoni F; Graham IR; Dickson G
Neuromuscul Disord; 2010 Feb; 20(2):102-10. PubMed ID: 20079639
[TBL] [Abstract][Full Text] [Related]
53. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.
Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G
Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011
[TBL] [Abstract][Full Text] [Related]
54. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
[TBL] [Abstract][Full Text] [Related]
55. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
56. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.
Saito T; Nakamura A; Aoki Y; Yokota T; Okada T; Osawa M; Takeda S
PLoS One; 2010 Aug; 5(8):e12239. PubMed ID: 20805873
[TBL] [Abstract][Full Text] [Related]
57. Design and Application of a Short (16-mer) Locked Nucleic Acid Splice-Switching Oligonucleotide for Dystrophin Production in Duchenne Muscular Dystrophy Myotubes.
Carvalho C; Carmo-Fonseca M
Methods Mol Biol; 2020; 2161():37-50. PubMed ID: 32681504
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
59. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.
Aoki Y; Nagata T; Yokota T; Nakamura A; Wood MJ; Partridge T; Takeda S
Hum Mol Genet; 2013 Dec; 22(24):4914-28. PubMed ID: 23882132
[TBL] [Abstract][Full Text] [Related]
60. Cationic polyelectrolyte-mediated delivery of antisense morpholino oligonucleotides for exon-skipping in vitro and in mdx mice.
Wang M; Wu B; Tucker JD; Lu P; Lu Q
Int J Nanomedicine; 2015; 10():5635-46. PubMed ID: 26366082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
